Medical Design Briefs - August 2024 - 17

Advanced devices are designed to
handle higher concentrations and
viscosities of therapeutic drugs.
(Credit: Jiraphiphat/AdobeStock)
FUTURE DEVELOPMENTS
To address the future developments in high-dose biologics
and their delivery devices, several key areas are likely to see
advancements that will enhance patient adherence, comfort,
and overall healthcare cost-efficiency:
Wearable Injectors. The development of more user-friendly,
smaller, and discreet wearable injectors will enable delivery of
high-dose biologics over a prolonged period, improving patient
comfort and adherence.
Smart Autoinjectors. Integration of smart technologies in
autoinjectors will provide real-time data on dosing, adherence,
and patient biometrics, allowing for personalized treatment
adjustments and better adherence tracking.
Advanced Formulations. Formulating biologics at higher
concentrations without increasing viscosity can reduce the volume
of injections and will make them less painful and more
convenient for patients. In addition, improved stabilization techniques
for biologics to ensure they remain effective and safe
over longer periods, reducing the need for frequent dosing and
increasing convenience.
Microneedle Technology. The further development of
micro needle patches will enable delivery of high-dose biologics
painlessly and efficiently through the skin, reducing the discomfort
associated with traditional injections. Selfadministration
will enable patients to take their medications
easily and safely at home, enhancing adherence and reducing
healthcare costs associated with clinic visits.
Nanoparticle Delivery Systems. Utilizing nanoparticles
for the targeted delivery of biologics will enhance their therapeutic
effect while minimizing side effects, thereby improving
patient outcomes and reducing overall treatment costs. Also,
the development of hydrogel-based delivery systems that release
biologics in a controlled manner over extended periods
will reduce the frequency of administration and will improve
the ability to target the delivery of biologics.
Digital Health Integration. Mobile health apps will enable
integration of delivery devices to remind patients to
take their medication, track adherence, and provide educational
support, enhancing overall adherence and patient engagement.
Integration with telemedicine will allow healthcare
providers to remotely monitor patient adherence and
respond to therapy through connected devices, enabling
timely interventions and personalized care adjustments.
Biosimilars and Biobetters. The development and approval
of biosimilars and biobetters will provide cost-effective alternatives
to existing high-dose biologics, increasing accessibility
for patients and reducing overall healthcare expenditures.
Manufacturing Innovations. Advancements in biomanufacturing
technologies will reduce production costs, improve scalability,
and ensure consistent quality of high-dose biologics, ultimately
lowering the cost for patients and healthcare systems.
Watch the slide show to see
examples of these future
developments.
Medical Design Briefs, August 2024
www.medicaldesignbriefs.com
17
https://www.medicaldesignbriefs.com
Medical Design Briefs - August 2024

Table of Contents for the Digital Edition of Medical Design Briefs - August 2024
